AntiObesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP1 Incretins and Uptake of Oral Treatments

Mordor Intelligence has published a new report on the AntiObesity Drugs Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction

Mordor Intelligence, in its latest antiobesity drugs market report, forecasts the market to reach from USD25.93billion in 2025 to USD100.97billion by 2030, advancing at a 31.24% CAGR. The anti-obesity drugs market [https://www.mordorintelligence.com/industry-reports/anti-obesity-drugs-market?utm_source=abnewswire] focuses on medications developed to aid in weight loss and manage obesity related conditions. Obesity is a chronic, relapsing condition associated with several health issues, including type 2 diabetes, cardiovascular diseases, sleep apnea, and certain cancers. As global obesity rates rise driven by sedentary lifestyles, poor dietary habits, and genetic factors, there is growing demand for medical interventions beyond lifestyle changes and bariatric surgery.

Key Trends

The antiobesity drugs landscape is being reshaped by several important developments:

1. GLP1 receptor agonists gaining dominance Guthormone incretins, primarily GLP1 agonists, are set to expand at 33.15% CAGR through 2030. Their strong efficacy in reducing weight and favorable safety profiles have led major pharmaceutical companies to scale up production and secure lifecycle extensions for these agents

2. Oral formulations on the rise Although injectables account for 81.3% of the 2024 market share, oral antiobesity drugs are projected to grow at an impressive 36.6% CAGR through 2030. This surge reflects patient preference for pill-based therapies and investment in oral GLP1 pills by developers.

3. Prescription segment maintains leadership Prescription drugs commanded 84.2% of the antiobesity drugs market in 2024. Overthecounter options trail behind but are gaining traction, with the prescription category still growing at a 32.56% CAGR through 2030

4. Digital pharmacies unlocking access Retail pharmacies held 54.05% of the market in 2024, but online pharmacies are catching up. They are expected to grow at a 34.75% CAGR, spurred by ecommerce ease and expanding reimbursement support.

5. AsiaPacific emerging fast North America remains the largest market with a 65.9% revenue share in 2024. However, AsiaPacific is advancing at a robust 33.65% CAGR, driven by rising healthcare spending and expanding obesity awareness.

Market Segmentation

The antiobesity drugs market can be segmented in multiple ways, enabling stakeholders to identify growth pockets and tailor strategies.

By Mechanism of Action

*
Peripherally acting drugs led revenue in 2024, capturing 60.10% of the market. These medications act within the digestive system, such as fatabsorption inhibitors and appetite suppressants, reducing energy uptake or signalling fullness.

*
Guthormone incretins (e.g., GLP1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through 2030. These therapies mimic or enhance gut hormones to regulate appetite and blood sugar.

By Drug Type

*
Prescription drugs held a dominant share at 84.20% in 2024. This category includes clinically validated medications with regulatory backing and reimbursement frameworks.

*
Overthecounter (OTC) drugs occupy a smaller share but are gradually gaining influence through ease of access and increasing consumer trust.

By Route of Administration

*
Injectables commanded 81.30% of the market in 2024, driven by the widespread use of injectable GLP1 therapies known for their strong efficacy.

*
Oral drugs are emerging as the most dynamic segment, projected to grow at a 36.60% CAGR from 2025 to 2030, reflecting a clear patient trend toward pills over injections.

By Distribution Channel

*
Retail pharmacies made up 54.05% of market revenues in 2024, remaining the standard way for patients to obtain antiobesity medications.

*
Online pharmacies are fast growing (projected 34.75% CAGR to 2030), propelled by telehealth, convenient home delivery, and evolving reimbursement policies.

By Geography

*
North America was the largest regional market, securing a 65.90% share in 2024. This dominance stems from advanced healthcare systems, approval frameworks, and strong payer support.

*
AsiaPacific is the fastest expanding region, with a projected CAGR of 33.65%. Growth drivers include rising obesity awareness, healthcare investments, and broader pharmaceutical access.

Key Players

Roche

Roche is a global pharmaceutical company that has recently entered the anti-obesity drugs market. The company has secured licensing agreements for potential weight loss candidates, signaling its interest in expanding its portfolio to include obesity treatments. Roche's expertise in biotechnology and commitment to addressing unmet medical needs position it as a noteworthy participant in the obesity care landscape.

GlaxoSmithKline (GSK)

GSK is a multinational healthcare company involved in the development of various therapeutic areas, including obesity. The company is exploring the potential of amylin analogs and other hormonal agents for weight management. GSK's research initiatives aim to provide patients with alternative treatment options and contribute to the advancement of obesity care.

Novo Nordisk

Novo Nordisk is a leading global healthcare company specializing in diabetes and obesity care. The company has developed several GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), which have shown significant efficacy in weight management. Novo Nordisk continues to invest in research and development to expand its portfolio of anti-obesity medications and enhance patient outcomes.

Currax Pharmaceuticals

Currax Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for obesity. Through strategic acquisitions, such as obtaining rights to Contrave, Currax has expanded its presence in the anti-obesity drugs market. The company's focus on addressing obesity-related health issues aligns with the growing demand for effective weight management therapies.

Eli Lilly and Company

Eli Lilly is another major player in the anti-obesity drugs market, known for its innovative therapies. The company's GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), has demonstrated promising results in clinical trials for weight loss. Eli Lilly's commitment to obesity care is reflected in its ongoing research efforts and strategic partnerships aimed at advancing treatment options for patients.

Conclusion

The antiobesity drugs market is entering a transformative era, with expected growth from USD25.93billion in 2025 to USD100.97billion by 2030 at a 31.24% CAGR. This growth is fuelled by the powerful clinical outcomes of GLP1 agonists, innovation in oral formulations, expanded access via online pharmacies, and increasing attention to obesity as a chronic disease.

While North America remains the dominant market, AsiaPacific's rapidly growing demand offers substantial opportunities. Competition is intensifying, as established pharmaceutical companies and biotechs alike race to advance next generation therapies and diversify distribution channels.

As market dynamics evolve, stakeholders should monitor:

- Progress of oral GLP1 candidates and dual/tripleagonists like CagriSema

- Regulatory approvals and reimbursement pathways, especially in emerging regions

- Competitive responses from lifecycle extensions to partnerships and acquisitions

- Supply chain robustness and accessibility, particularly amid supply constraints for highdemand drugs

In sum, the antiobesity drugs market is poised for significant expansion, with transformative treatments and shifting delivery models likely to reshape global healthcare delivery and patient outcomes.

For More insights: https://www.mordorintelligence.com/industry-reports/anti-obesity-drugs-market?utm_source=abnewswire

Industry Related Reports

Ozempic Market : [https://www.mordorintelligence.com/industry-reports/ozempic-market?utm_source=abnewswire] The Ozempic Market Report is segmented by region, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report provides both value (in USD) and volume (in units) for each of these segments.

Japan Oral Anti-Diabetic Drug Market: The Japan Oral Anti-Diabetic Drug Market Report is segmented by drug types, including Biguanides, Alpha-Glucosidase Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, and others, as well as end users, such as Hospitals/Clinics, Personal/Home Care Settings, and others. The report provides market size and forecasts for each segment in terms of value (USD).

Get More Insights: https://www.mordorintelligence.com/industry-reports/japan-oral-anti-diabetic-drug-market?utm_source=abnewswire

Anti-Snoring Market: [https://www.mordorintelligence.com/industry-reports/anti-snoring-treatment-market?utm_source=abnewswire] The Anti-Snoring Devices Market report segments the industry by device type, including Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) Devices, and other device types. It also segments by surgical procedures such as Uvulopalatopharyngoplasty (UPPP), Somnoplasty, Pillar Procedure, Tonsillectomy, Radiofrequency Palatoplasty, and more. Additionally, the report covers geographical segmentation.

About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact: media@mordorintelligence.com https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=antiobesity-drugs-market-to-reach-usd-10097-billion-by-2030-driven-by-glp1-incretins-and-uptake-of-oral-treatments]
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.